Skip to main content
Top
Published in: BMC Neurology 1/2016

Open Access 01-12-2016 | Research article

Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases

Authors: Ursula Werneke, Fariba Jamshidi, David M. Taylor, Michael Ott

Published in: BMC Neurology | Issue 1/2016

Login to get access

Abstract

Background

Serotonin syndrome is a toxic state, caused by serotonin (5HT) excess in the central nervous system. Serotonin syndrome’s main feature is neuro-muscular hyperexcitability, which in many cases is mild but in some cases can become life-threatening. The diagnosis of serotonin syndrome remains challenging since it can only be made on clinical grounds. Three diagnostic criteria systems, Sternbach, Radomski and Hunter classifications, are available. Here we test the validity of four assumptions that have become widely accepted: (1) The Hunter classification performs clinically better than the Sternbach and Radomski criteria; (2) in contrast to neuroleptic malignant syndrome, the onset of serotonin syndrome is usually rapid; (3) hyperthermia is a hallmark of severe serotonin syndrome; and (4) serotonin syndrome can readily be distinguished from neuroleptic malignant syndrome on clinical grounds and on the basis of medication history.

Methods

Systematic review and meta-analysis of all cases of serotonin syndrome and toxicity published between 2004 and 2014, using PubMed and Web of Science.

Results

Two of the four assumptions (1 and 2) are based on only one published study each and have not been independently validated. There is little agreement between current criteria systems for the diagnosis of serotonin syndrome. Although frequently thought to be the gold standard for the diagnosis of the serotonin syndrome, the Hunter criteria did not perform better than the Sternbach and Radomski criteria. Not all cases seem to be of rapid onset and only relatively few cases may present with hyperthermia. The 0 differential diagnosis between serotonin syndrome and neuroleptic malignant syndrome is not always clear-cut.

Conclusions

Our findings challenge four commonly made assumptions about serotonin syndrome. We propose our meta-analysis of cases (MAC) method as a new way to systematically pool and interpret anecdotal but important clinical information concerning uncommon or emergent phenomena that cannot be captured in any other way but through case reports.
Appendix
Available only for authorised users
Literature
2.
go back to reference Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7:587–96.CrossRefPubMed Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7:587–96.CrossRefPubMed
3.
go back to reference Sclar DA, Robison LM, Castillo LV, Schmidt JM, Bowen KA, Oganov AM, Skaer TL, Kogut SJ. Concomitant use of triptan, and SSRI or SNRI after the US food and drug administration alert on serotonin syndrome. Headache. 2012;52:198–203.CrossRefPubMed Sclar DA, Robison LM, Castillo LV, Schmidt JM, Bowen KA, Oganov AM, Skaer TL, Kogut SJ. Concomitant use of triptan, and SSRI or SNRI after the US food and drug administration alert on serotonin syndrome. Headache. 2012;52:198–203.CrossRefPubMed
4.
go back to reference Evans RW. The FDA, alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. Med Gen Med. 2007;9:48. Evans RW. The FDA, alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. Med Gen Med. 2007;9:48.
6.
go back to reference Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55:218–24.CrossRefPubMed Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55:218–24.CrossRefPubMed
7.
go back to reference Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–42.CrossRefPubMed Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–42.CrossRefPubMed
8.
go back to reference MacKay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871–4.PubMedPubMedCentral MacKay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871–4.PubMedPubMedCentral
9.
10.
go back to reference Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006;59:1046–51.CrossRefPubMed Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006;59:1046–51.CrossRefPubMed
12.
go back to reference Cohen J. A coefficient of agreement for nominal scale. Educat Psychol Measure. 1960;20:37–46.CrossRef Cohen J. A coefficient of agreement for nominal scale. Educat Psychol Measure. 1960;20:37–46.CrossRef
13.
go back to reference Centers for Disease Control and Prevention (CDC). Twenty-five years of HIV/AIDS--United States, 1981–2006. MMWR Morb Mortal Wkly Rep. 2006;55(21):585–9. Centers for Disease Control and Prevention (CDC). Twenty-five years of HIV/AIDS--United States, 1981–2006. MMWR Morb Mortal Wkly Rep. 2006;55(21):585–9.
14.
go back to reference Streiner DL, Norman GR. Health measurement scales. A practical guide to their development and use. 2nd ed. Oxford: Oxford University Press; 1995. Streiner DL, Norman GR. Health measurement scales. A practical guide to their development and use. 2nd ed. Oxford: Oxford University Press; 1995.
15.
16.
go back to reference Goodstein DL, Neugebauer G. Special preface (from lectures of physics). In: Six easy pieces. The fundamentals of physics explained (RP Feynman). London: Penguin; 1995. p. xvii–xxi. Goodstein DL, Neugebauer G. Special preface (from lectures of physics). In: Six easy pieces. The fundamentals of physics explained (RP Feynman). London: Penguin; 1995. p. xvii–xxi.
17.
go back to reference Prakash S, Gosai F, Brahmbhatt J, Shah C. Serotonin syndrome in patients with peripheral neuropathy: a diagnostic challenge. Gen Hospital Psychiatry. 2014;36:450 e9–11.CrossRef Prakash S, Gosai F, Brahmbhatt J, Shah C. Serotonin syndrome in patients with peripheral neuropathy: a diagnostic challenge. Gen Hospital Psychiatry. 2014;36:450 e9–11.CrossRef
18.
go back to reference Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79:201–9.CrossRef Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79:201–9.CrossRef
19.
go back to reference Morales Molina JA, Mateu-De Antonio J, Marin-Casino M, Grau S. Linezolid-associated serotonin syndrome: what can we learn from cases reported so far. J Antimicrob Chemother. 2005;56:1176–8.CrossRefPubMed Morales Molina JA, Mateu-De Antonio J, Marin-Casino M, Grau S. Linezolid-associated serotonin syndrome: what can we learn from cases reported so far. J Antimicrob Chemother. 2005;56:1176–8.CrossRefPubMed
20.
go back to reference Marlowe K, Schirgel D. Quetiapine and citalopram: aetiological significances in serotonin syndrome. NZ Med J. 2006;119:U2058. Marlowe K, Schirgel D. Quetiapine and citalopram: aetiological significances in serotonin syndrome. NZ Med J. 2006;119:U2058.
22.
go back to reference Wappler F, Fiege M, Schulte Am Esch J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth. 2001;87:794–8.CrossRefPubMed Wappler F, Fiege M, Schulte Am Esch J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth. 2001;87:794–8.CrossRefPubMed
23.
go back to reference Niederkofler V, Asher TE, Dymecki SM. Functional interplay between dopaminergic and serotonergic neuronal systems during development and adulthood. ACS Chem Neurosci. 2015;6:1055–70.CrossRefPubMedPubMedCentral Niederkofler V, Asher TE, Dymecki SM. Functional interplay between dopaminergic and serotonergic neuronal systems during development and adulthood. ACS Chem Neurosci. 2015;6:1055–70.CrossRefPubMedPubMedCentral
24.
go back to reference Schwartz TL, Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci Ther. 2011;17:110–7.CrossRefPubMed Schwartz TL, Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci Ther. 2011;17:110–7.CrossRefPubMed
26.
go back to reference Tricoci P, Allen JM, Kramer JM, Califf RM, Smith Jr SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831–41.CrossRefPubMed Tricoci P, Allen JM, Kramer JM, Califf RM, Smith Jr SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831–41.CrossRefPubMed
27.
go back to reference Kahneman D. Thinking fast and slow. New York: Farrar, Straus and Gireaux; 2011. Kahneman D. Thinking fast and slow. New York: Farrar, Straus and Gireaux; 2011.
Metadata
Title
Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases
Authors
Ursula Werneke
Fariba Jamshidi
David M. Taylor
Michael Ott
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2016
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-016-0616-1

Other articles of this Issue 1/2016

BMC Neurology 1/2016 Go to the issue